X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (345) 345
oncology (273) 273
female (258) 258
male (252) 252
middle aged (239) 239
aged (228) 228
adult (202) 202
index medicus (184) 184
lung neoplasms - drug therapy (153) 153
chemotherapy (102) 102
carcinoma, non-small-cell lung - drug therapy (101) 101
cancer (93) 93
antineoplastic combined chemotherapy protocols - therapeutic use (85) 85
treatment outcome (85) 85
chemistry (82) 82
metallurgy (81) 81
lung neoplasms - pathology (78) 78
pharmacology & pharmacy (67) 67
physics (67) 67
lung cancer (66) 66
japan (63) 63
neoplasms - drug therapy (59) 59
cisplatin (54) 54
cisplatin - administration & dosage (54) 54
aged, 80 and over (52) 52
compositions based thereon (51) 51
medicine & public health (51) 51
organic macromolecular compounds (51) 51
their preparation or chemical working-up (51) 51
antineoplastic agents - therapeutic use (49) 49
care and treatment (48) 48
carcinoma, non-small-cell lung - pathology (47) 47
drug administration schedule (47) 47
neoplasm staging (47) 47
tumors (47) 47
cinematography (46) 46
electrography (46) 46
electrophotography (46) 46
holography (46) 46
lung cancer, non-small cell (46) 46
magnetography (46) 46
photography (46) 46
lung neoplasms - mortality (45) 45
dose-response relationship, drug (44) 44
non-small cell lung cancer (44) 44
analysis (43) 43
research (43) 43
retrospective studies (42) 42
pharmacology/toxicology (41) 41
antineoplastic combined chemotherapy protocols - adverse effects (40) 40
antineoplastic agents - adverse effects (39) 39
cancer research (38) 38
compositions of macromolecular compounds (38) 38
pharmacokinetics (38) 38
performing operations (37) 37
transporting (37) 37
gefitinib (36) 36
prognosis (36) 36
respiratory system (36) 36
trial (36) 36
medical research (34) 34
therapy (33) 33
animals (32) 32
lung neoplasms - genetics (32) 32
carboplatin (31) 31
expression (31) 31
general tagging of cross-sectional technologies spanning over several sections of the ipc (31) 31
general tagging of new technological developments (31) 31
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (31) 31
technical subjects covered by former uspc (30) 30
camptothecin - analogs & derivatives (29) 29
disease-free survival (29) 29
mutation (29) 29
carcinoma, non-small-cell lung - mortality (28) 28
docetaxel (28) 28
antineoplastic agents - administration & dosage (27) 27
cell line, tumor (27) 27
cell lung-cancer (27) 27
paclitaxel (27) 27
survival (27) 27
survival analysis (27) 27
medicine, experimental (26) 26
survival rate (26) 26
lung neoplasms - metabolism (25) 25
maximum tolerated dose (25) 25
hematology, oncology and palliative medicine (24) 24
lung neoplasms - therapy (24) 24
oncology, experimental (24) 24
paclitaxel - administration & dosage (24) 24
toxicity (24) 24
antimitotic agents (23) 23
antineoplastic agents (23) 23
carcinoma (23) 23
etoposide - administration & dosage (23) 23
mice (23) 23
original (23) 23
small cell lung cancer (23) 23
technical subjects covered by former us classification (23) 23
adenocarcinoma - drug therapy (22) 22
antineoplastic agents - pharmacokinetics (22) 22
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (727) 727
Japanese (34) 34
French (32) 32
German (23) 23
Korean (4) 4
Chinese (2) 2
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability... 
Internal Medicine | ANAPLASTIC LYMPHOMA KINASE | MEDICINE, GENERAL & INTERNAL | SAFETY | CH5424802 | AF-001JP | ADVANCED NSCLC | INHIBITORS | CHEMOTHERAPY | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Medical services | Metastasis | Kinases | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Cut-off | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Journal Article
Cancer Science, ISSN 1347-9032, 05/2017, Volume 108, Issue 5, pp. 1000 - 1006
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 14, pp. 1692 - 1698
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 106 - 113
Journal Article
Cancer Science, ISSN 1347-9032, 11/2016, Volume 107, Issue 11, pp. 1642 - 1646
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2008, Volume 26, Issue 26, pp. 4244 - 4252
Purpose This phase III study (V-15-32) compared gefitinib (250 mg/d) with docetaxel (60 mg/m(2)) in patients (N = 489) with advanced/metastatic non-small-cell... 
IRESSA | SURVIVAL | SUPPORTIVE CARE | VINORELBINE | EFFICACY | ONCOLOGY | PLATINUM-BASED CHEMOTHERAPY | RANDOMIZED-TRIAL | OPEN-LABEL | 60 MG/M | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans